Acadia Pharma Q4 NUPLAZID sales $136.5M, full-year $517.2M; PDUFA for trofinetide March 12

ACADIA PHARMACEUTICALS INC

2022-FY EPS reported -$1.34 revenue$517,235,000

Net sales $517.2M in 2022, up 7% YoY; Q4 sales $136.5M, up 4% YoY.
Net loss $216.0M for 2022 vs $167.9M in 2021; Q4 loss $41.7M ($0.26/share).
PDUFA action date March 12, 2023 for trofinetide for Rett syndrome.
2023 guidance: NUPLAZID sales $520-550M; R&D $235-255M; SG&A $360-380M.
Doug Williamson appointed EVP Head of R&D in Jan 2023; Serge Stankovic retired.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACADIA PHARMACEUTICALS INC reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 27, 2023, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACADIA PHARMACEUTICALS INC reported financial results for the full year ended December 31, 2022.

Period: the full year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 27, 2023, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-004753

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.